{"analyses":[{"ciLowerLimit":"19.6","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"36.1","estimateComment":"Strata adjusted difference (Arm C - Concurrent Arm B) based on the CMH method of weighting. Stratified by PD-L1 (≥ 1% vs \\<1%/unevaluable/indeterminate), disease stage (IB/II vs IIIA), and sex (male vs female)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"% Difference","paramValue":"27.9"},{"ciLowerLimit":"3.16","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"10.26","estimateComment":"Stratified by PD-L1 (≥ 1% vs \\<1%/unevaluable/indeterminate), disease stage (IB/II vs IIIA), and sex (male vs female)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"5.70"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"66"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"179"}],"units":"Participants"}],"description":"Major pathologic response (MPR) rate is defined as number of randomized participants with \\</= 10% residual tumor in lung and lymph nodes as evaluated by blinded independent pathological review (BIPR). Viable tumors in situ carcinoma should not be included in MPR calculation.","groups":[{"description":"Participants receive investigator-choice of platinum doublet chemotherapy regimens in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days).\n\nFollowing definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.","id":"OG000","title":"Arm B: Platinum Doublet Chemo"},{"description":"Participants receive nivolumab 360 mg IV + platinum doublet chemotherapy in 3-week cycles up to a maximum of 3 cycles of IV chemotherapy (ie, 9 weeks of treatment; each cycle is 21 days).\n\nFollowing definitive surgery, participants could receive up to 4 cycles of adjuvant chemotherapy and/or radiation at the discretion of the investigator.","id":"OG001","title":"Arm C: Nivo 360 mg + Platinum Doublet Chemo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All concurrently randomized participants in Arm C and Arm B","reportingStatus":"POSTED","timeFrame":"From randomization up to a median of 30 months after randomization.","title":"Major Pathologic Response (MPR) Rate","type":"SECONDARY","unitOfMeasure":"Participants"}